Focus on extracellular vesicles: Development of extracellular vesicle-based therapeutic systems

International Journal of Molecular Sciences

Volumn 17, Issue 2, 2016, Pages

  Ohno, Shin Ichiro ^a   Drummen, Gregor P C ^b   Kuroda, Masahiko ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

^b Bio and Nano Solutions   (Germany)

Author keywords

Clinical trial; Dexosome; Drug delivery system; Exosome; Extracellular vesicle; Microvesicle; Outer membrane vesicle; Stem cell; Vaccine

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; CHITOSAN; CURCUMIN; CYCLODEXTRIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FACTOR H BINDING PROTEIN; GAMMA INTERFERON; GE11 PEPTIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; LIPOSOME; MACROGOL; MELANOMA ANTIGEN 3; MENPF 1 VACCINE; MESSENGER RNA; MICRORNA 133B; MICRORNA 146B; MICRORNA 150; NANOCARRIER; NEISSERIAL ADHESIN A; NEISSERIAL HEPARIN BINDING ANTIGEN; PACLITAXEL; PEPTIDES AND PROTEINS; RECOMBINANT VACCINE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANTIBODY TITER; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; BONE MARROW DERIVED DENDRITIC CELL; DRUG APPROVAL; DRUG DELIVERY SYSTEM; EXOSOME; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; MEMBRANE MICROPARTICLE; MESENCHYMAL STEM CELL; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; ANIMAL; CLINICAL TRIAL (TOPIC); IMMUNOLOGY; METABOLISM; NEOPLASMS; STEM CELL; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; ANTIGEN-PRESENTING CELLS; BIOLOGICAL TRANSPORT; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; EXOSOMES; EXTRACELLULAR VESICLES; HUMANS; NEOPLASMS; STEM CELLS;

EID: 84957552185     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms17020172     Document Type: Review

References (120)

1. Théry, C., Ostrowski, M., Segura, E. Membrane vesicles as conveyors of immune responses. Nat. Rev. Immunol. 2009, 9, 581-593.
2. Kalra, H., Drummen, G.P. C., Mathivanan, S. Focus on extracellular vesicles: Exosomes, the next small big thing. Int. J. Mol. Sci. 2016, 17, doi:10.3390/ijms17020170.
3. Théry, C., Amigorena, S., Raposo, G., Clayton, A. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr. Protoc. Cell Biol. 2006, doi:10.1002/0471143030.cb0322s30.
4. Camussi, G., Deregibus, M.C., Bruno, S., Grange, C., Fonsato, V., Tetta, C. Exosome/microvesicle-mediated epigenetic reprogramming of cells. Am. J. Cancer Res. 2011, 1, 98-110.
5. Cocucci, E., Racchetti, G., Meldolesi, J. Shedding microvesicles: Artefacts no more. Trends Cell Biol. 2009, 19, 43-51.
6. Théry, C., Boussac, M., Véron, P., Ricciardi-Castagnoli, P., Raposo, G., Garin, J., Amigorena, S. Proteomic analysis of dendritic cell-derived exosomes: A secreted subcellular compartment distinct from apoptotic vesicles. J. Immunol. 2001, 166, 7309-7318.
7. Food and Drug Administration (US), Drugs@FDA, Silver Spring (MD). Available online: www.fda.gov (accessed on 17 January 2016).
8. European Medicines Agency (EU), Find Medicines, London (UK). Available online: www.ema.europa.eu (accessed on 17 January 2016).
9. National Library of Medicine (US), ClinicalTrials.gov, Bethesda (MD). Available online: www.clinicaltrials.gov. (accessed on 17 January 2016).
10. Szebeni, J. Complement activation-related pseudoallergy caused by liposomes, micellar carriers of intravenous drugs, and radiocontrast agents. Crit. Rev. Ther. Drug Carrier. Syst. 2001, 18, 567-606.
11. Szebeni, J. Complement activation-related pseudoallergy: A new class of drug-induced acute immune toxicity. Toxicology 2005, 216, 106-121.
12. Haney, M.J., Klyachko, N.L., Zhao, Y., Gupta, R., Plotnikova, E.G., He, Z., Patel, T., Piroyan, A., Sokolsky, M., Kabanov, A.V., et al. Exosomes as drug delivery vehicles for Parkinson's disease therapy. J. Control. Release 2015, 207, 18-30.
13. Nagasaki, Y. Construction of a densely poly(ethylene glycol)-chain-tethered surface and its performance. Polym. J. 2011, 43, 949-958.
14. Suk, J.S., Xu, Q., Kima, N., Hanes, J., Ensign, L.M. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv. Drug Deliv. Rev. 2015, doi:10.1016/j.addr.2015.09.012.
15. Leger, R.M., Arndt, P., Garratty, G., Armstrong, J., Meiselman, H., Fisher, T. Normal donor sera can contain antibodies to polyethylene glycol (PEG). Transfusion 2001, 41, 29S.
16. Armstrong, J., Leger, R., Wenby, R., Meiselman, H., Garratty, G., Fisher, T. Occurrence of an antibody to poly(ethylene glycol) in normal donors. Blood 2003, 102, 566A.
17. Armstrong, J.K., Hempel, G., Koling, S., Chan, L.S., Fisher, T., Meiselman, H.J., Garratty, G. Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer 2007, 110, 103-111.
18. U.S. Food and Drug Administration, Select Committee on GRAS Substances opinion: Propylene glycol and propylene glycol monostearate. SCOGS Database 1973. Available online: www.fda.gov (accessed on 5 January 2016).
19. Fuhrmann, G., Serio, A., Mazo, M., Nair, R., Stevens, M.M. Active loading into extracellular vesicles significantly improves the cellular uptake and photodynamic effect of porphyrins. J. Control. Release 2015, 205, 35-44.
20. Alvarez-Erviti, L., Seow, Y., Yin, H., Betts, C., Lakhal, S., Wood, M.J. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat. Biotechnol. 2011, 29, 341-345.
21. Ohno, S., Takanashi, M., Sudo, K., Ueda, S., Ishikawa, A., Matsuyama, N., Fujita, K., Mizutani, T., Ohgi, T., Ochiya, T., et al. Systemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells. Mol. Ther. 2013, 21, 185-191.
22. Kooijmans, S., Stremersch, S., Braeckmans, K., de Smedt, S., Hendrix, A., Wood, M., Schiffelers, R.M., Raemdonck, K., Vader, P. Electroporation-induced siRNA precipitation obscures the efficiency of siRNA loading into extracellular vesicles. J. Control. Release 2013, 172, 229-238.
23. Zeelenberg, I.S., Ostrowski, M., Krumeich, S., Bobrie, A., Jancic, C., Boissonnas, A., Delcayre, A., Le Pecq, J.B., Combadiere, B., Amigorena, S., et al. Targeting tumor antigens to secreted membrane vesicles in vivo induces efficient antitumor immune responses. Cancer Res. 2008, 68, 1228-1235.
24. Haney, M.J., Zhao, Y., Harrison, E.B., Mahajan, V., Ahmed, S., He, Z., Suresh, P., Hingtgen, S.D., Klyachko, N.L., Mosley, R.L., et al. Specific transfection of inflamed brain by macrophages: A new therapeutic strategy for neurodegenerative diseases. PLoS ONE 2013, 8, e61852.
25. Maguire, C.A., Balaj, L., Sivaraman, S., Crommentuijn, M.H., Ericsson, M., Mincheva-Nilsson, L., Baranov, V., Gianni, D., Tannous, B.A., Sena-Esteves, M., et al. Microvesicle-associated AAV vector as a novel gene delivery system. Mol. Ther. 2012, 20, 960-971.
26. DiMarino, A.M., Caplan, A., Bonfield, T.L. Mesenchymal stem cells in tissue repair. Front. Immunol. 2013, 4, 201.
27. Frenette, P.S., Pinho, S., Lucas, D., Scheiermann, C. Mesenchymal stem cell: Keystone of the hematopoietic stem cell niche and a stepping-stone for regenerative medicine. Annu. Rev. Immunol. 2013, 31, 285-316.
28. Curley, G.F., Ansari, B., Hayes, M., Devaney, J., Masterson, C., Ryan, A., Barry, F., O’Brien, T., Toole, D.O., Laffey, J.G. Effects of intratracheal mesenchymal stromal cell therapy during recovery and resolution after ventilator-induced lung injury. Anesthesiology 2013, 118, 924-932.
29. Li, G., Yuan, L., Ren, X., Nian, H., Zhang, L., Han, Z.C., Li, X., Zhang, X. The effect of mesenchymal stem cells on dynamic changes of T cell subsets in experimental autoimmune uveoretinitis. Clin. Exp. Immunol. 2013, 173, 28-37.
30. Johnson, T.V., Bull, N.D., Hunt, D.P., Marina, N., Tomarev, S.I., Martin, K.R. Neuroprotective effects of intravitreal mesenchymal stem cell transplantation in experimental glaucoma. Investig. Ophthalmol. Vis. Sci. 2010, 51, 2051-2059.
31. Bouchez, G., Sensebé, L., Vourc’h, P., Garreau, L., Bodard, S., Rico, A., Guilloteau, D., Charbord, P., Besnard, J.C., Chalon, S. Partial recovery of dopaminergic pathway after graft of adult mesenchymal stem cells in a rat model of Parkinson's disease. Neurochem. Int. 2008, 52, 1332-1342.
32. Mazzini, L., Mareschi, K., Ferrero, I., Miglioretti, M., Stecco, A., Servo, S., Carriero, A., Monaco, F., Fagioli, F. Mesenchymal stromal cell transplantation in amyotrophic lateral sclerosis: a long-term safety study. Cytotherapy 2012, 14, 56-60.
33. Mazzini, L., Vercelli, A., Mareschi, K., Ferrero, I., Testa, L., Fagioli, F. Mesenchymal stem cells for ALS patients. Amyotroph. Lateral. Scl. 2009, 10, 123-124.
34. Liang, J., Zhang, H., Hua, B., Wang, H., Wang, J., Han, Z., Sun, L. Allogeneic mesenchymal stem cells transplantation in treatment of multiple sclerosis. Mult. Scl. 2009, 15, 644-646.
35. Kordelas, L., Rebmann, V., Ludwig, A.K., Radtke, S., Ruesing, J., Doeppner, T.R., Epple, M., Horn, P.A., Beelen, D.W., Giebel, B. MSC-derived exosomes: A novel tool to treat therapy-refractory graft-versus-host disease. Leukemia 2014, 28, 970-973.
36. Schafer, A., Pahnke, A., Schaffert, D., van Weerden, W.M., de Ridder, C.M., Rodl, W., Vetter, A., Spitzweg, C., Kraaij, R., Wagner, E., et al. Disconnecting the yin and yang relation of epidermal growth factor receptor (EGFR)-mediated delivery: A fully synthetic, EGFR-targeted gene transfer system avoiding receptor activation. Hum. Gene Ther. 2011, 22, 1463-1473.
37. Chen, J.Y., An, R., Liu, Z.J., Wang, J.J., Chen, S.Z., Hong, M.M., Liu, J.H., Xiao, M.Y., Chen, Y.F. Therapeutic effects of mesenchymal stem cell-derived microvesicles on pulmonary arterial hypertension in rats. Acta Pharmacol. Sin. 2014, 35, 1121-1128.
38. Zhu, Y.G., Feng, X.M., Abbott, J., Fang, X.H., Hao, Q., Monsel, A., Qu, J.M., Matthay, M.A., Lee, J.W. Human mesenchymal stem cell microvesicles for treatment of Escherichia coli endotoxin-induced acute lung injury in mice. Stem Cells 2014, 32, 116-125.
39. Blin, G., Nury, D., Stefanovic, S., Neri, T., Guillevic, O., Brinon, B., Bellamy, V., Rücker-Martin, C., Barbry, P., Bel, A., et al. A purified population of multipotent cardiovascular progenitors derived from primate pluripotent stem cells engrafts in postmyocardial infarcted nonhuman primates. J. Clin. Investig. 2010, 120, 1125-1139.
40. Caspi, O., Huber, I., Kehat, I., Habib, M., Arbel, G., Gepstein, A., Yankelson, L., Aronson, D., Beyar, R., Gepstein, L. Transplantation of human embryonic stem cell-derived cardiomyocytes improves myocardial performance in infarcted rat hearts. J. Am. Coll. Cardiol. 2007, 50, 1884-1893.
41. Khan, M., Nickoloff, E., Abramova, T., Johnson, J., Verma, S.K., Krishnamurthy, P., Mackie, A.R., Vaughan, E., Garikipati, V.N., Benedict, C., et al. Embryonic stem cell-derived exosomes promote endogenous repair mechanisms and enhance cardiac function following myocardial infarction. Circ. Res. 2015, 117, 52-64.
42. Bruno, S., Grange, C., Deregibus, M.C., Calogero, R.A., Saviozzi, S., Collino, F., Morando, L., Busca, A., Falda, M., Bussolati, B., et al. Mesenchymal stem cell-derived microvesicles protect against acute tubular injury. J. Am. Soc. Nephrol. 2009, 20, 1053-1067.
43. Gatti, S., Bruno, S., Deregibus, M.C., Sordi, A., Cantaluppi, V., Tetta, C., Camussi, G. Microvesicles derived from human adult mesenchymal stem cells protect against ischaemia-reperfusion-induced acute and chronic kidney injury. Nephrol. Dial. Transplant. 2011, 26, 1474-1483.
44. Yu, B., Zhang, X., Li, X. Exosomes derived from mesenchymal stem cells. Int. J. Mol. Sci. 2014, 15, 4142-4157.
45. Raposo, G., Nijman, H.W., Stoorvogel, W., Liejendekker, R., Harding, C.V., Melief, C.J., Geuze, H.J. B lymphocytes secrete antigen-presenting vesicles. J. Exp. Med. 1996, 183, 1161-1172.
46. Nolte’t Hoen, E.N., Buschow, S.I., Anderton, S.M., Stoorvogel, W., Wauben, M.H. Activated T cells recruit exosomes secreted by dendritic cells via LFA-1. Blood 2009, 113, 1977-1981.
47. Muntasell, A., Berger, A.C., Roche, P.A. T cell-induced secretion of MHC class II-peptide complexes on B cell exosomes. EMBO J. 2007, 26, 4263-4272.
48. Martin-Jaular, L., Nakayasu, E.S., Ferrer, M., Almeida, I.C., Del Portillo, H.A. Exosomes from Plasmodium yoelii-infected reticulocytes protect mice from lethal infections. PLoS ONE 2011, 6, e26588.
49. Näslund, T.I., Gehrmann, U., Qazi, K.R., Karlsson, M.C., Gabrielsson, S. Dendritic cell-derived exosomes need to activate both T and B cells to induce antitumor immunity. J. Immunol. 2013, 190, 2712-2719.
50. Qazi, K.R., Gehrmann, U., Domange Jordö, E., Karlsson, M.C., Gabrielsson, S. Antigen-loaded exosomes alone induce Th1-type memory through a B-cell-dependent mechanism. Blood 2009, 113, 2673-2683.
51. Damo, M., Wilson, D.S., Simeoni, E., Hubbell, J.A. TLR-3 stimulation improves anti-tumor immunity elicited by dendritic cell exosome-based vaccines in a murine model of melanoma. Sci. Rep. 2015, 5, 17622.
52. Bianco, N.R., Kim, S.H., Ruffner, M.A., Robbins, P.D. Therapeutic effect of exosomes from indoleamine 2,3-dioxygenase-positive dendritic cells in collagen-induced arthritis and delayed-type hypersensitivity disease models. Arthritis Rheum. 2009, 60, 380-389.
53. Prado, N., Marazuela, E.G., Segura, E., Fernández-García, H., Villalba, M., Théry, C., Rodríguez, R., Batanero, E. Exosomes from bronchoalveolar fluid of tolerized mice prevent allergic reaction. J. Immunol. 2008, 181, 1519-1525.
54. Kim, S.H., Bianco, N.R., Shufesky, W.J., Morelli, A.E., Robbins, P.D. Effective treatment of inflammatory disease models with exosomes derived from dendritic cells genetically modified to express IL-4. J. Immunol. 2007, 179, 2242-2249.
55. Kim, S.H., Bianco, N., Menon, R., Lechman, E.R., Shufesky, W.J., Morelli, A.E., Robbins, P.D. Exosomes derived from genetically modified DC expressing FasL are anti-inflammatory and immunosuppressive. Mol. Ther. 2006, 13, 289-300.
56. Admyre, C., Johansson, S.M., Qazi, K.R., Filén, J.J., Lahesmaa, R., Norman, M., Neve, E.P., Scheynius, A., Gabrielsson, S. Exosomes with immune modulatory features are present in human breast milk. J. Immunol. 2007, 179, 1969-1978.
57. Aucher, A., Rudnicka, D., Davis, D.M. MicroRNAs transfer from human macrophages to hepato-carcinoma cells and inhibit proliferation. J. Immunol. 2013, 191, 6250-6260.
58. Squadrito, M.L., Baer, C., Burdet, F., Maderna, C., Gilfillan, G.D., Lyle, R., Ibberson, M., De Palma M. Endogenous RNAs modulate microRNA sorting to exosomes and transfer to acceptor cells. Cell. Rep. 2014, 8, 1432-1446.
59. Buck, A.H., Coakley, G., Simbari, F., McSorley, H.J., Quintana, J.F., Le Bihan, T., Kumar, S., Abreu-Goodger, C., Lear, M., Harcus, Y., et al. Exosomes secreted by nematode parasites transfer small RNAs to mammalian cells and modulate innate immunity. Nat. Commun. 2014, 5, 5488.
60. Nono, J.K., Pletinckx, K., Lutz, M.B., Brehm, K. Excretory/secretory-products of Echinococcus multilocularis larvae induce apoptosis and tolerogenic properties in dendritic cells in vitro. PLoS Negl. Trop. Dis. 2012, 6, e1516.
61. Marcilla, A., Trelis, M., Cortes, A., Sotillo, J., Cantalapiedra, F., Minguez, M.T., Valero, M.L., Sanchez del Pino, M.M., Munoz-Antoli, C., Toledo, R., et al. Extracellular vesicles from parasitic helminths contain specific excretory/secretory proteins and are internalized in intestinal host cells. PLoS ONE 2012, 7, e45974.
62. Robbins, P.D., Morelli, A.E. Regulation of immune responses by extracellular vesicles. Nat. Rev. Immunol. 2014, 14, 195-208.
63. Tian, Y., Li, S., Song, J., Ji, T., Zhu, M., Anderson, G.J., Wei, J., Nie, G. A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. Biomaterials 2014, 35, 2383-2390.
64. Jang, S.C., Kim, O.Y., Yoon, C.M., Choi, D.S., Roh, T.Y., Park, J., Nilsson, J., Lötvall, J., Kim, Y.K., Gho, Y.S. Bioinspired exosome-mimetic nanovesicles for targeted delivery of chemotherapeutics to malignant tumors. ACS Nano 2013, 7, 7698-7710.
65. Guo, F., Chang, C.K., Fan, H.H., Nie, X.X., Ren, Y.N., Liu, Y.Y., Zhao, L.H. Anti-tumour effects of exosomes in combination with cyclophosphamide and polyinosinic-polycytidylic acid. J. Int. Med. Res. 2008, 36, 1342-1353.
66. Pascucci, L., Coccè, V., Bonomi, A., Ami, D., Ceccarelli, P., Ciusani, E., Viganò, L., Locatelli, A., Sisto, F., Doglia, S.M., et al. Paclitaxel is incorporated by mesenchymal stromal cells and released in exosomes that inhibit in vitro tumor growth: A new approach for drug delivery. J. Control. Release 2014, 192, 262-270.
67. Federici, C., Petrucci, F., Caimi, S., Cesolini, A., Logozzi, M., Borghi, M., D’llio, S., Lugini, L., Violante, N., Azzarito, T., et al. Exosome release and low pH belong to a framework of resistance of human melanoma cells to cisplatin. PLoS ONE 2014, 9, e88193.
68. Takahashi, M., Uechi, S., Takara, K., Asikin, Y., Wada, K. Evaluation of an oral carrier system in rats: Bioavailability and antioxidant properties of liposome-encapsulated curcumin. J. Agric. Food Chem. 2009, 57, 9141-9146.
69. Ray, B., Bisht, S., Maitra, A., Maitra, A., Lahiri, D.K. Neuroprotective and neurorescue effects of a novel polymeric nanoparticle formulation of curcumin (NanoCurc) in the neuronal cell culture and animal model: Implications for Alzheimer's disease. J. Alzheimers Dis. 2011, 23, 61-77.
70. Tomren, M.A., Masson, M., Loftsson, T., Tonnesen, H.H. Studies on curcumin and curcuminoids XXXI. Symmetric and asymmetric curcuminoids: Stability, activity and complexation with cyclodextrin. Int. J. Pharm. 2007, 338, 27-34.
71. Akhtar, F., Rizvi, M.M., Kar, S.K. Oral delivery of curcumin bound to chitosan nanoparticles cured Plasmodium yoelii infected mice. Biotechnol. Adv. 2012, 30, 310-320.
72. Shaikh, J., Ankola, D.D., Beniwal, V., Singh, D., Kumar, M.N. Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer. Eur. J. Pharm. Sci. 2009, 37, 223-230.
73. Sun, D., Zhuang, X., Xiang, X., Liu, Y., Zhang, S., Liu, C., Barnes, S., Grizzle, W., Miller, D., Zhang, H.G. A novel nanoparticle drug delivery system: The anti-inflammatory activity of curcumin is enhanced when encapsulated in exosomes. Mol. Ther. 2010, 18, 1606-1614.
74. Zhuang, X., Xiang, X., Grizzle, W., Sun, D., Zhang, S., Axtell, R.C., Ju, S., Mu, J., Zhang, L., Steinman, L., et al. Treatment of brain inflammatory diseases by delivering exosome encapsulated anti-inflammatory drugs from the nasal region to the brain. Mol. Ther. 2011, 19, 1769-1779.
75. Gupta, S.C., Patchva, S., Aggarwal, B.B. Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J. 2013, 15, 195-218.
76. Osterman, C.J., Lynch, J.C., Leaf, P., Gonda, A., Ferguson Bennit, H.R., Griffiths, D., Wall, N.R. Curcumin modulates pancreatic adenocarcinoma cell-derived exosomal function. PLoS ONE 2015, 10, e0132845.
77. Valadi, H., Ekström, K., Bossios, A., Sjöstrand, M., Lee, J.J., Lötvall, J.O. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol. 2007, 9, 654-659.
78. Xin, H., Li, Y., Buller, B., Katakowski, M., Zhang, Y., Wang, X., Shang, X., Zhang, Z.G., Chopp, M. Exosome-mediated transfer of miR-133b from multipotent mesenchymal stromal cells to neural cells contributes to neurite outgrowth. Stem Cells 2012, 30, 1556-1564.
79. Katakowski, M., Buller, B., Zheng, X., Lu, Y., Rogers, T., Osobamiro, O., Shu, W., Jiang, F., Chopp, M. Exosomes from marrow stromal cells expressing miR-146b inhibit glioma growth. Cancer Lett. 2013, 335, 201-204.
80. Yeo, R.W., Lai, R.C., Zhang, B., Tan, S.S., Yin, Y., Teh, B.J., Lim, S.K. Mesenchymal stem cell: An efficient mass producer of exosomes for drug delivery. Adv. Drug Deliv. Rev. 2013, 65, 336-341.
81. Bryniarski, K., Ptak, W., Jayakumar, A., Püllmann, K., Caplan, M.J., Chairoungdua, A., Lu, J., Adams, B.D., Sikora, E., Nazimek, K., et al. Antigen-specific, antibody-coated, exosome-like nanovesicles deliver suppressor T-cell microRNA-150 to effector T cells to inhibit contact sensitivity. J. Allergy Clin. Immunol. 2013, 132, 170-181.
82. Escudier, B., Dorval, T., Chaput, N., André, F., Caby, M.P., Novault, S., Flament, C., Leboulaire, C., Borg, C., Amigorena, S., et al. Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial. J. Transl. Med. 2005, 3, 10.
83. Morse, M.A., Garst, J., Osada, T., Khan, S., Hobeika, A., Clay, T.M., Valente, N., Shreeniwas, R., Sutton, M.A., Delcayre, A., et al. A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J. Transl. Med. 2005, 3, 9.
84. Dai, S., Wei, D., Wu, Z., Zhou, X., Wei, X., Huang, H., Li, G. Phase I clinical trial of autologous ascites-derived exosomes combined with GM-CSF for colorectal cancer. Mol. Ther. 2008, 16, 782-790.
85. Thomas Jefferson University Hospital, Pilot immunotherapy trial for recurrent malignant gliomas. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US) 2000. Available online: https://clinicaltrials.gov/show/NCT01550523 (accesssed on 12 January 2016).
86. Viaud, S., Ploix, S., Lapierre, V., Thery, C., Commere, P.H., Tramalloni, D., Gorrichon, K., Virault-Rocroy, P., Tursz, T., Lantz, O., et al. Updated technology to produce highly immunogenic dendritic cell-derived exosomes of clinical grade: A critical role of interferon-gamma. J. Immunother. 2011, 34, 65-75.
87. Sahel Teaching Hospital; Faculty of Medicine Cairo University, Effect of microvesicles and exosomes therapy on β-cell mass in type I diabetes mellitus (T1DM). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US) 2000. Available online: https://clinicaltrials.gov/show/NCT02138331 (accesssed on 12 January 2016).
88. Sandbu, S., Feiring, B., Oster, P., Helland, O.S., Bakke, H.S., Naess, L.M., Aase, A., Aaberge, I.S., Kristoffersen, A.C., Rydland, K.M., et al. Immunogenicity and safety of a combination of two serogroup B meningococcal outer membrane vesicle vaccines. Clin. Vaccine Immunol. 2007, 14, 1062-1069.
89. Marsay, L., Dold, C., Green, C.A., Rollier, C.S., Norheim, G., Sadarangani, M., Shanyinde, M., Brehony, C., Thompson, A.J., Sanders, H., et al. A novel meningococcal outer membrane vesicle vaccine with constitutive expression of FetA: A phase I clinical trial. J. Infect. 2015, 71, 326-337.
90. James Graham Brown Cancer Center; University of Louisville, Study investigating the ability of plant exosomes to deliver curcumin to normal and colon cancer tissue. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US) 2000. Available online: https://clinicaltrials.gov/show/NCT01294072 (accesssed on 12 January 2016).
91. James Graham Brown Cancer Center; University of Louisville, Edible plant exosome ability to prevent oral mucositis associated with chemoradiation treatment of head and neck cancer. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US) 2000. Available online: https://clinicaltrials.gov/show/NCT01668849 (accesssed on 12 January 2016).
92. Findlow, J., Borrow, R., Snape, M.D., Dawson, T., Holland, A., John, T.M., Evans, A., Telford, K.L., Ypma, E., Toneatto, D., et al. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin. Infect. Dis. 2010, 51, 1127-1137.
93. Harshyne, L.A., Hooper, K.M., Andrews, E.G., Nasca, B.J., Kenyon, L.C., Andrews, D.W., Hooper, D.C. Glioblastoma exosomes and IGF-1R/AS-ODN are immunogenic stimuli in a translational research immunotherapy paradigm. Cancer Immunol. Immunother. 2015, 64, 299-309.
94. Morin-Brureau, M., Hooper, K.M., Prosniak, M., Sauma, S., Harshyne, L.A., Andrews, D.W., Hooper, D.C. Enhancement of glioma-specific immunity in mice by “NOBEL”, an insulin-like growth factor 1 receptor antisense oligodeoxynucleotide. Cancer Immunol. Immunother. 2015, 64, 447-457.
95. Andrews, D.W. Thomas Jefferson University Hospital, Pilot immunotherapy trial for recurrent malignant gliomas. Personal communication, 20 January 2016.
96. Navabi, H., Croston, D., Hobot, J., Clayton, A., Zitvogel, L., Jasani, B., Bailey-Wood, R., Wilson, K., Tabi, Z., Mason, M.D., et al. Preparation of human ovarian cancer ascites-derived exosomes for a clinical trial. Blood Cells Mol. Dis. 2005, 35, 149-152.
97. Van der Pol, L., Stork, M., van der Ley, P. Outer membrane vesicles as platform vaccine technology. Biotechnol. J. 2015, 10, 1689-1706.
98. Gujrati, V., Kim, S., Kim, S.H., Min, J.J., Choy, H.E., Kim, S.C., Jon, S. Bioengineered bacterial outer membrane vesicles as cell-specific drug-delivery vehicles for cancer therapy. ACS Nano 2014, 8, 1525-1537.
99. Knight, S.D., Parrish, C.A. Recent progress in the identification and clinical evaluation of inhibitors of the mitotic kinesin KSP. Curr. Top. Med. Chem. 2008, 8, 888-904.
100. Tao, W.K., South, V.J., Zhang, Y., Davide, J.P., Farrell, L., Kohl, N.E., Sepp-Lorenzino, L., Lobell, R.B. Induction of apoptosis by an inhibitor of the mitotic kinesin KSP requires both activation of the spindle assembly checkpoint and mitotic slippage. Cancer Cell 2005, 8, 49-59.
101. Kim, S.H., Kim, K.S., Lee, S.R., Kim, E., Kim, M.S., Lee, E.Y., Gho, Y.S., Kim, J.W., Bishop, R.E., Chang, K.T. Structural modifications of outer membrane vesicles to refine them as vaccine delivery vehicles. Biochim. Biophys. Acta 2009, 1788, 2150-2059.
102. Somerville, J.E., Jr., Cassiano, L., Darveau, R.P. Escherichia coli msbB gene as a virulence factor and a therapeutic target. Infect. Immun. 1999, 67, 6583-6590.
103. Mathivanan, S., Lim, J.W., Tauro, B.J., Ji, H., Moritz, R.L., Simpson, R.J. Proteomics analysis of A33 immunoaffinity-purified exosomes released from the human colon tumor cell line LIM1215 reveals a tissue-specific protein signature. Mol. Cell. Proteom. 2010, 9, 197-208.
104. McCready, J., Sims, J.D., Chan, D., Jay, D.G. Secretion of extracellular hsp90α via exosomes increases cancer cell motility: a role for plasminogen activation. BMC Cancer 2010, 10, 294.
105. Ochieng, J., Pratap, S., Khatua, A.K., Sakwe, A.M. Anchorage-independent growth of breast carcinoma cells is mediated by serum exosomes. Exp. Cell Res. 2009, 315, 1875-1888.
106. Skog, J., Wurdinger, T., van Rijn, S., Meijer, D.H., Gainche, L., Sena-Esteves, M., Curry, W.T., Carter, B.S., Krichevsky, A.M., Breakefield, X.O. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat. Cell Biol. 2008, 10, 1470-1476.
107. Lagana, A., Russo, F., Veneziano, D., Bella, S.D., Giugno, R., Pulvirenti, A., Croce, C.M., Ferro, A. Extracellular circulating viral microRNAs: current knowledge and perspectives. Front. Genet. 2013, 4, 120.
108. Delabranche, X., Berger, A., Boisrame-Helms, J., Meziani, F. Microparticles and infectious diseases. Med. Mal. Infect. 2012, 42, 335-343.
109. Schwab, A., Meyering, S.S., Lepene, B., Iordanskiy, S., van Hoek, M.L., Hakami, R.M., Kashanchi, F. Extracellular vesicles from infected cells: potential for direct pathogenesis. Front. Microbiol. 2015, 6, 1132.
110. Hu, G.W., Li, Q., Niu, X., Hu, B., Liu, J., Zhou, S.M., Guo, S.C., Lang, H.L., Zhang, C.Q., Wang, Y., Deng, Z.F. Exosomes secreted by human-induced pluripotent stem cell-derived mesenchymal stem cells attenuate limb ischemia by promoting angiogenesis in mice. Stem Cell Res. Ther. 2015, 6, 10.
111. Trajkovic, K., Hsu, C., Chiantia, S., Rajendran, L., Wenzel, D., Wieland, F., Schwille, P., Brügger, B., Simons, M. Ceramide triggers budding of exosome vesicles into multivesicular endosomes. Science 2008, 319, 1244-1247.
112. Hurley, J.H., Odorizzi, G. Get on the exosome bus with ALIX. Nat. Cell Biol. 2012, 14, 654-655.
113. Baietti, M.F., Zhang, Z., Mortier, E., Melchior, A., Degeest, G., Geeraerts, A., Ivarsson, Y., Depoortere, F., Coomans, C., Vermeiren, E., et al. Syndecan-syntenin-ALIX regulates the biogenesis of exosomes. Nat. Cell Biol. 2012, 14, 677-685.
114. Asai, H., Ikezu, S., Tsunoda, S., Medalla, M., Luebke, J., Haydar, T., Wolozin, B., Butovsky, O., Kügler, S., Ikezu, T. Depletion of microglia and inhibition of exosome synthesis halt tau propagation. Nat. Neurosci. 2015, 18, 1584-1593.
115. Vilette, D., Laulagnier, K., Huor, A., Alais, S., Simoes, S., Maryse, R., Provansal, M., Lehmann, S., Andreoletti, O., Schaeffer, L., et al. Efficient inhibition of infectious prions multiplication and release by targeting the exosomal pathway. Cell. Mol. Life Sci. 2015, 72, 4409-4427.
116. Ramakrishnaiah, V., Thumann, C., Fofana, I., Habersetzer, F., Pan, Q., de Ruiter, P.E., Willemsen, R., Demmers, J.A., Stalin Raj, V., Jenster, G., et al. Exosome-mediated transmission of hepatitis C virus between human hepatoma Huh7.5 cells. Proc. Natl. Acad. Sci. USA 2013, 110, 13109-13113.
117. Zhang, B., Tan, K.H., Lim, S.K. Focus on extracellular vesicles: Therapeutic efficacy of stem cell-derived extracellular vesicles. Int. J. Mol. Sci. 2016, 17, doi:10.3390/ijms17020174.
118. Vella, L.J., Hill, A.F., Cheng, L. Focus on extracellular vesicles: Exosomes and their role in protein trafficking in Alzheimer’s and Parkinson’s disease. Int. J. Mol. Sci. 2016, 17, doi:10.3390/ijms17020173.
119. Iraci, N., Leonardi, T., Gessler, F., Vega, B., Pluchino, S. Focus on extracellular vesicles: Physiological role and signaling properties of extracellular membrane vesicles. Int. J. Mol. Sci. 2016, 17, doi:10.3390/ijms17020171.
120. Ciardiello, C., Cavallini, L., Spinelli, C., Yang, J., Reis-Sobreiro, M., de Candia, P., Rene’ Minciacchi, V., di Vizio, D. Focus on extracellular vesicles: New frontiers of cell-to-cell communication in cancer. Int. J. Mol. Sci. 2016, 17, doi:10.3390/ijms17020175.